Trial Profile
A Phase III Trial of ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transplantation (UCBT) in Patients With Inborn Errors of Metabolism
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2014
Price :
$35
*
At a glance
- Drugs ALD 101 (Primary)
- Indications Adrenoleucodystrophy; Alpha-Mannosidosis; Canavan disease; Fucosidosis; Gangliosidoses; Globoid cell leukodystrophy; Metachromatic leukodystrophy; Mucolipidoses; Mucopolysaccharidosis I; Mucopolysaccharidosis II; Mucopolysaccharidosis III; Mucopolysaccharidosis VI; Niemann-Pick diseases; Pelizaeus-Merzbacher disease; Tay-Sachs disease
- Focus Therapeutic Use
- Sponsors Aldagen
- 07 Jul 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 12 May 2014 New trial record